249 related articles for article (PubMed ID: 33038489)
1. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
[TBL] [Abstract][Full Text] [Related]
2. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
[TBL] [Abstract][Full Text] [Related]
3. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
[TBL] [Abstract][Full Text] [Related]
7. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
8. Transmembrane protein 106C promotes the development of hepatocellular carcinoma.
Luo X; Han G; Lu R; Guan S; Wang Y; Ju L; Chen L; Shao J; Bian Z
J Cell Biochem; 2020 Nov; 121(11):4484-4495. PubMed ID: 32037603
[TBL] [Abstract][Full Text] [Related]
9. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL
Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523
[TBL] [Abstract][Full Text] [Related]
10. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
Sun XF; Sun JP; Hou HT; Li K; Liu X; Ge QX
Tumour Biol; 2016 Nov; 37(11):15325-15332. PubMed ID: 27704356
[TBL] [Abstract][Full Text] [Related]
13. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
Ying D; Ruan Y; Zhou X
Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
[TBL] [Abstract][Full Text] [Related]
14. cIAP2 via NF-κB signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Jiang XJ; Chen ZW; Zhao JF; Liao CX; Cai QH; Lin J
Life Sci; 2021 Feb; 266():118867. PubMed ID: 33310033
[TBL] [Abstract][Full Text] [Related]
15. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma.
Liu Z; Li W; Pang Y; Zhou Z; Liu S; Cheng K; Qin Q; Jia Y; Liu S
EBioMedicine; 2018 Dec; 38():57-68. PubMed ID: 30391496
[TBL] [Abstract][Full Text] [Related]
16. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein.
Gao J; Dai C; Yu X; Yin XB; Zhou F
FASEB J; 2020 Apr; 34(4):5800-5817. PubMed ID: 32128906
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.
Guo C; Zhou S; Yi W; Yang P; Li O; Liu J; Peng C
Exp Mol Pathol; 2021 Jun; 120():104638. PubMed ID: 33878313
[TBL] [Abstract][Full Text] [Related]
19. lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
Zhuang R; Zhang X; Lu D; Wang J; Zhuo J; Wei X; Ling Q; Xie H; Zheng S; Xu X
Mol Carcinog; 2019 Mar; 58(3):366-375. PubMed ID: 30362626
[TBL] [Abstract][Full Text] [Related]
20. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
